Director, Global Scientific Affairs
As Director of Global Scientific Affairs, Dr. Benmaamar advances the Health, Science, and Technology agenda by ensuring that all scientific content from the Foundation adheres to most rigorous scientific standards, and is designed to inform appropriate stakeholders (e.g., researchers, policy makers, and consumers). She also contributes to developing the Foundation’s scientific engagement strategy.
Prior to joining the Foundation, Dr. Benmaamar was Manager of Global Publications and Scientific Communications, Oncology Business Group, at Eisai Pharmaceuticals. She managed the global communication of the results of clinical trials, and the review process of scientific and medical documents prior to their publication in peer-review journals and their presentation at scientific meetings.
Before working at Eisai, Dr. Benmaamar was Senior Researcher at New York University, Langone Medical Center, Radiation Oncology. She managed pancreatic cancer research. She helped design innovative research projects to better understand the various molecular, immunological, and metabolic aspects of pancreatic cancer. In earlier years, Dr. Benmaamar was Associate Director of Medical Communications at medical communication agencies, partnering with pharmaceuticals to develop scientific content for presentations at conferences and advisory boards, and for patient and healthcare provider websites.
In addition to her scientific experience, Dr. Benmaamar worked at the United Nations as a Conference Manager. She facilitated and coordinated a wide range of conferences such as those of the World Health Organization (WHO), United Nations Children’s Fund (UNICEF), Human Rights Committee, General Assembly, Indigenous Peoples’ Forum, and Conference of the Parties (COP 20) to the United Nations Framework Convention on Climate Change. She speaks four of the six United Nations official languages (English, French, Arabic, and Spanish), as well as Italian.
Dr. Benmaamar is a seasoned freelance writer for The Lancet Oncology, mainly communicating groundbreaking results of clinical trials on several types of cancer. She holds a PhD in Pharmacology from Univerisité Louis Pasteur, Strasbourg, France